


Systemische therapie mHSPC

Steve Boudewijns
Internist oncoloog

10-2023

Disclosures

Geen



10 jaar aan studies


TABLE 1. Summary Data of Completed Trials in Metastatic Hormone-Sensitive Prostate Cancer
Doublet Systemic Therapy

Trial	Patients Enrolled	Intervention Arm	Control Arm	Previous/ Concurrent Docetaxel	Median Follow-Up (months)	Median OS in Intervention Arm (months)	Median OS in Control Arm (months)	Group: HR (95% CI)	P
CHAARTED ⁷	790	ADT plus docetaxel	ADT	Not allowed	53.7	57.6	47.2	0.72 (0.59 to 0.89)	.0018
STAMPEDE (M1 subgroup) ⁸	1,086	ADT plus docetaxel	ADT	Not allowed	78.2	59.1	43.1	0.81 (0.69 to 0.95)	.003
LATITUDE ¹⁰	1,199	ADT plus abiraterone plus prednisone	ADT plus placebo	Not allowed	51.8	53.3	36.5	0.66 (0.56 to 0.78)	<.0001
STAMPEDE ⁹	1,917	ADT plus abiraterone plus prednisone	ADT	Not allowed	40	NR	NR	Overall: 0.63 (0.52 to 0.76) M1 subgroup: 0.61 (0.49 to 0.75)	<.001 (overall)
ENZAMET ¹⁶	1,125	ADT plus enzalutamide	ADT plus NSAA	Allowed (concurrent, 45%)	68	NR	NR	Overall: 0.70 (0.58 to 0.84) Early docetaxel: 0.82 (0.63 to 1.06) No early docetaxel: 0.60 (0.47 to 0.78)	<.0001 (overall)
ARCHES ¹¹	1,150	ADT plus enzalutamide	ADT plus placebo	Allowed (previous, 18%)	44.6	NR	NR	Overall: 0.66 (0.53 to 0.81) Previous docetaxel: 0.74 (0.46 to 1.20) No previous docetaxel: 0.64 (0.51 to 0.81)	<.001 (overall)
TITAN ¹²	1,052	ADT plus apalutamide	ADT plus placebo	Allowed (previous, 11%)	44	NR	52.2	Overall: 0.65 (0.53 to 0.79) Previous docetaxel: 1.12 (0.59 to 2.12) No previous docetaxel: 0.61 (0.50 to 0.76)	<.0001 (overall)


Triplet Systemic Therapy

Trial	Patients Enrolled	Intervention Arm	Control Arm	% Synchronous	% High-Volume	Median Follow-Up (months)	Median OS in Intervention Arm (months)	Median OS in Control Arm (months)	Group: HR (95% CI)
ARASENS ^{13,14}	1,306	ADT plus docetaxel plus darolutamide	ADT plus docetaxel plus placebo	86	77	43.7	NR	48.9	Overall: 0.68 (0.57 to 0.80) Synchronous + HV: 0.69 (0.57 to 0.85) Synchronous + LV: 0.75 (0.45 to 1.27) Metachronous + HV: 0.69 (0.39 to 1.24) Metachronous + LV: NA
PEACE-1 (docetaxel subgroup) ¹⁵	710	SOC plus abiraterone (with or without RT)	SOC (with or without RT)	100	64	45.6	NR	53.2	Overall (all synchronous): 0.75 (0.59 to 0.95)
ENZAMET (docetaxel subgroup) ¹⁶	503	ADT plus docetaxel plus enzalutamide	ADT plus docetaxel plus NSAA	72	71	68 (overall cohort)	Not reported	Not reported	Synchronous (all): 0.73 (0.55 to 0.99) Synchronous + HV: 0.79 (0.57 to 1.10) Synchronous + LV: 0.57 (0.29 to 1.12) Metachronous (all): 1.10 (0.65 to 1.86)


CHAARTED: ADT +/- Docetaxel





STAMPEDE overzicht




STAMPEDE arm C: ADT +/- Docetaxel



Post-hoc Analyse (CHAARTED)




Upfront androgeen receptor signaal inhibitoren (ARSI's)



LATITUDE: ADT +/- Abitateron

Inclusie: de novo mHSPC met minstens 2/3 hoog risico factoren:


- Gleason score ≥ 8
-
-




	Number at risk (number censored)											
	0	6	12	18	24	30	36	42	48	54	60	66
Abiraterone acetate and prednisone plus ADT	597	565 (14)	529 (28)	479 (34)	425 (42)	389 (46)	351 (50)	311 (57)	240 (106)	124 (205)	40 (282)	0 (322)
Placebos plus ADT	602	564 (17)	505 (34)	432 (47)	368 (58)	315 (37)	256 (74)	220 (79)	165 (114)	69 (197)	23 (237)	0 (259)

STAMPEDE arm G: ADT +/- Abirateron

OS totale M1 populatie




Post-hoc Analyse (LATITUDE)



Hoog risico

SOC									
At-risk	232	206	152	106	73	56	28	6	0
Censored	0	2	5	5	6	13	33	51	54
Died	0	24	75	121	153	163	171	175	178
SOC+AAP									
At-risk	241	221	191	154	124	111	66	19	1
Censored	0	2	2	3	5	9	39	79	95
Died	0	18	48	84	112	121	136	143	145




Laag risico

SOC									
At-risk	220	212	190	165	146	109	62	29	1
Censored	0	2	3	4	5	14	50	77	101
Died	0	6	27	51	69	97	108	114	118
SOC+AAP									
At-risk	208	206	187	167	156	144	92	30	5
Censored	0	0	2	5	5	6	43	103	128
Died	0	2	19	36	47	58	73	75	75

ENZAMET: ADT + enzalutamide/NSAA

Enzamet




S:
ISAA): 73.2 mo (64.7 - NR)
side: NR (NR - NR)

vival:
ISAA): 57%
side: 67%

low-up: 68 months

TITAN: ADT + Apalutamide/placebo



No. at risk:


Apalutamide	525	513	489	452	425	394	362	227	52	3	0
Placebo	527	510	474	436	374	339	301	181	43	0	0

Discussie upfront Docetaxel/ARSI

- Welke beeldvorming gebruiken voor bepalen volume status
- Welke ARSI?
- Verschil bij hoogvolume/laagvolume of hoogrisico/laagrisico
- Duur behandeling
- Plaats van radiotherapie (STAMPEDE arm H)

Outcome measure	Patient group	Adjusted HR [†]	Unadjusted HR [‡]	Event free at 5 years [‡]		RMST [†]		
				SOC	SOC +RT	SOC	SOC+RT	Difference
OS	All patients	0.90 (0.81 to 1.01)	0.90 (0.81 to 1.01)	42%	45%	52.9	55.5	2.5 (-0.2 to 5.2)
	Low metastatic burden	0.64 (0.52 to 0.79)	0.66 (0.54 to 0.82)	53%	65%	60.6	69.0	8.4 (4.5 to 12.2)
	High metastatic burden	1.11 (0.96 to 1.28)	1.08 (0.94 to 1.25)	35%	30%	47.7	45.5	-2.2 (-5.7 to 1.2)

PEACE 1: ADT + Docetaxel + Abi in de Novo mHSPC



	Patients assessed, n		Median, years		Median difference, years	Hazard ratio	p value
	SOC with abiraterone groups	SOC without abiraterone groups	SOC with abiraterone groups	SOC without abiraterone groups			
Primary outcomes in the overall population							
Overall survival	583	589	5.7	4.7	0.9 (95.1% CI 0.0-2.0)	0.82 (95.1% CI 0.69-0.98)	0.030
Radiographic progression-free survival	583	589	4.5	2.2	2.1 (99.9% CI 0.7-2.9)	0.54 (99.9% CI 0.41-0.71)	<0.0001
Secondary outcomes in the overall population							
CRPC-free survival	583	589	3.8	1.5	2.3 (95% CI 1.6-3.0)	0.40 (95% CI 0.35-0.47)	<0.0001
Prostate-cancer-specific survival	583	589	NR	5.8	NA	0.75 (95% CI 0.61-0.91)	0.0038
Primary outcomes in the ADT with docetaxel population							
Overall survival	355	355	NR	4.4	NA	0.75 (95.1% CI 0.59-0.95)	0.017
Radiographic progression-free survival	355	355	4.5	2.0	2.2 (99.9% CI 0.6-2.8)	0.50 (99.9% CI 0.34-0.71)	<0.0001
Secondary outcomes in the ADT with docetaxel population							
Overall survival in patients with low-volume metastatic burden	131	123	NR	NR	NA	0.83 (95.1% CI 0.50-1.39)	0.66
Overall survival in patients with high-volume metastatic burden	224	232	5.1	3.5	1.1 (95.1% CI 0.2-1.9)	0.72 (95.1% CI 0.55-0.95)	0.019
Radiographic progression-free survival in patients with low-volume metastatic burden	129	122	NR	2.7	NA	0.58 (99.9% CI 0.29-1.15)	0.0061
Radiographic progression-free survival in patients with high-volume metastatic burden	225	231	4.1	1.6	2.2 (99.9% CI 0.6-3.2)	0.47 (99.9% CI 0.30-0.72)	<0.0001
CRPC-free survival	355	355	3.2	1.4	2.0 (95% CI 1.5-3.1)	0.38 (95% CI 0.31-0.47)	<0.0001
Prostate-cancer-specific survival	355	355	NR	4.7	NA	0.69 (95% CI 0.53-0.90)	0.0062

	ADT with docetaxel population		ADT without docetaxel population	
	SOC plus abiraterone groups (with or without radiotherapy; n=347)	SOC without abiraterone groups (with or without radiotherapy; n=350)	SOC plus abiraterone groups (with or without radiotherapy; n=226)	SOC without abiraterone groups (with or without radiotherapy; n=237)
Any adverse events	346 (100%)	349 (100%)	226 (100%)	233 (99%)
Severe (grade ≥ 3) adverse events	217 (63%)	181 (52%)	149 (66%)	97 (41%)
Fatal (grade 5) adverse events	7 (2%)	3 (1%)	8 (4%)	5 (2%)
Frequent severe adverse events				
Hypertension	76 (22%)	45 (13%)	66 (29%)	38 (16%)
Neutropenia	34 (10%)	32 (9%)	0	0
Hepatotoxicity	20 (6%)	2 (1%)	14 (6%)	3 (1%)
Febrile neutropenia	18 (5%)	19 (5%)	2 (1%)	1 (<1%)
Gamma-glutamyl transferase increase	17 (5%)	14 (4%)	6 (3%)	4 (2%)
Erectile dysfunction	7 (2%)	5 (1%)	12 (5%)	13 (5%)
Blood alkaline phosphatase increase	15 (4%)	12 (3%)	6 (3%)	13 (5%)
Other severe adverse events				
Fatigue	10 (3%)	15 (4%)	3 (1%)	0
Peripheral neuropathy	4 (1%)	6 (2%)	1 (<1%)	0

Data are n (%). As the patients were not randomly assigned according to docetaxel prescription, toxicities recorded in the ADT without docetaxel and ADT with docetaxel populations are not directly comparable. Percentages are rounded to the nearest integer. The safety population includes patients who actually received the assigned treatment. Severe adverse events (grade ≥ 3) were considered frequent if they occurred in at least 5% of patients in either group and are reported in decreasing order of occurrence according to the Medical Dictionary for Regulatory Affairs Preferred Term classification. ADT=androgen deprivation therapy. SOC=standard of care.

Table 3: Adverse events in the safety population

ARASENS: ADT + Docetaxel +/- Darolutamide in mHSPC




Figure 1. Overall Survival (Pooled Analysis)

Hoog volume


Laag volume

Table 3. Adverse Events.*

Event	Darolutamide–ADT–Docetaxel (N = 652)†	Placebo–ADT–Docetaxel (N = 650)†
	<i>number of patients (percent)</i>	
Any adverse event	649 (99.5)	643 (98.9)
Worst grade		
Grade 1	28 (4.3)	35 (5.4)
Grade 2	162 (24.8)	169 (26.0)
Grade 3	248 (38.0)	232 (35.7)
Grade 4	183 (28.1)	181 (27.8)
Grade 5	27 (4.1)	26 (4.0)
Serious adverse event	292 (44.8)	275 (42.3)
Adverse event leading to permanent discontinuation of trial agent		
Darolutamide or placebo	88 (13.5)	69 (10.6)
Docetaxel	52 (8.0)	67 (10.3)
Selected grade 3 or 4 adverse events‡		
Neutropenia§	220 (33.7)	222 (34.2)
Febrile neutropenia	51 (7.8)	48 (7.4)
Hypertension	42 (6.4)	21 (3.2)
Anemia	31 (4.8)	33 (5.1)
Pneumonia	21 (3.2)	20 (3.1)
Hyperglycemia	18 (2.8)	24 (3.7)
Increased ALT level	18 (2.8)	11 (1.7)
Increased AST level	17 (2.6)	7 (1.1)
Increased weight	14 (2.1)	8 (1.2)
Urinary tract infection	13 (2.0)	12 (1.8)

Discussie triple therapie

- Opzet PEACE 1 studie
- Docetaxel met abirateron versus abirateron alleen
- Synergistisch effect ARSI en docetaxel?
- Patient reported outcomes/QoL
- Hoe lang door met ARSI in deze vorm van behandeling
- Alle hoog volume patienten triple therapie?



- Radiotherapie prostaat
- ARSI
- Studiebehandeling

- Docetaxel
- ARSI
- Triple therapie
- Studiebehandeling

Take home messages

- Intensivering behandeling heeft positief effect op overleving
- Moet alles bij iedereen?